Onkologie. 2022:16(4):206-211 | DOI: 10.36290/xon.2022.039

New treatment options for cutaneous T-cell lymphomas

Miriam Ladická
Klinika onkohematológie LF UK a Národného onkologického ústavu, Bratislava

Review article summarizing new treatment options for cutaneous T-cell lymphomas.

Keywords: cutaneous T-cell lymphomas, treatment options.

Accepted: August 22, 2022; Published: August 24, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ladická M. New treatment options for cutaneous T-cell lymphomas. Onkologie. 2022;16(4):206-211. doi: 10.36290/xon.2022.039.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Trautinger F, Eder J, Assaf Ch, et al. Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. European Journal of Can­cer 2017;77:57-74. Go to original source... Go to PubMed...
    2. Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sézary syndrome. Blood. 2016;127(25):3142-3153. Go to original source... Go to PubMed...
    3. Available from: https://www.ema.europa.eu/en/documents/assessment-report/poteligeo-epar-public-assessment-report_en.pdf.
    4. Musiek ACM, Rieger KE. Martine Bagot M, et al. Dermatologic Events Associated with (Heidelb). Available from: https:// doi.org/10.1007/s13555-021-00624-7. Go to original source... Go to PubMed...
    5. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphomas (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1192-204. Go to original source... Go to PubMed...
    6. Zinzani PL, Horwitz S, Kim YH, et al. Mogamulizumab Efficacy by Prior Systemic Therapy in Patients Previously Treated For Cutaneous T-Cell Lymphoma: a MAVORIC Study Post-Hoc Analysis. T-Cell Lymphoma Forum 2019, poster.
    7. Kim YH. What factors guide treatment selection in mycosis fungoides and Sezary syndrome? Hematology 2021, ASH Education Program: 303-312. Go to original source...
    8. Polívka J. Mogamulizumab: nová léčba pokročilých stadií kožních T buněčných lymfomů - mycosis fungoides a Sézaryho syndromu. Onkologie. 2021;15:187-193. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.